AngioDynamics, Inc. (ANGO) vs CytomX Therapeutics, Inc. (CTMX)
A side-by-side comparison of AngioDynamics, Inc. and CytomX Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANGO
AngioDynamics, Inc.
$14.75HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
CTMX
CytomX Therapeutics, Inc.
$2.62HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — ANGO vs CTMX
growth of $100 · dividends reinvested · last 10yANGO -11.4% (-1.2%/yr)CTMX -83.1% (-16.3%/yr)ANGO compounded faster over this window
Log scale — wide-divergence pair
ANGO CTMX
ANGO vs CTMX: by the numbers
- •ANGO is the larger company ($610M vs $569M market cap).
- •Both run net losses; ANGO's is the smaller (-11.48% vs -435.21% net margin).
- •CTMX grew revenue faster over the past five years (2.18% vs 1.93% CAGR).
Metrics side by side
Valuation
| Metric | ANGO | CTMX |
|---|---|---|
| P/S ratio | 1.90 | 31.11 |
| P/B ratio | 3.57 | 1.88 |
| FCF yield | 0.08% | N/A |
Profitability
| Metric | ANGO | CTMX |
|---|---|---|
| Gross margin | 54.62% | 98.63% |
| Operating margin | -12.47% | -29.35% |
| Net margin | -11.48% | -435.21% |
| ROE | -21.51% | -26.37% |
| ROIC | -20.75% | -25.42% |
Growth (annualized)
| Metric | ANGO | CTMX |
|---|---|---|
| Revenue CAGR (5Y) | 1.93% | 2.18% |
| FCF CAGR (5Y) | -51.49% | N/A |
| Total return CAGR (5Y) | -10.80% | -12.01% |
Frequently asked
- Which has grown faster, ANGO or CTMX?
- Over the past five years, CTMX grew revenue faster — ANGO at a 1.93% CAGR versus CTMX at 2.18%.
- How have ANGO and CTMX total returns compared?
- Over the past 10 years, ANGO delivered -0.58% and CTMX delivered -16.62% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.